USFDA Approved Latest Drug for Lung Cancer Patients
Beacon Pharmaceuticals Limited, the leading oncology company in Bangladesh, has introduced a groundbreaking treatment for lung cancer: Tagrix, the first global generic version of osimertinib.
Learn more
Insights
Founded in 2006, Beacon Pharmaceuticals is a leading Bangladeshi pharmaceutical company. It excels in oncology and biotech medicines, contributing 22.6% of Bangladesh's pharmaceutical exports to 135 countries. Beyond medicines, Beacon promotes health through initiatives like the Global Patient Support Program and Beacon Point, a CSR-driven addiction treatment center.
